

- An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. *Bone Marrow Transplant*. 2003;31:667-678.
78. McMahon S, Wood M, Cole M. The essential cofactor TRRAP recruits the histone acetyltransferase hGCN5 to c-Myc. *Mol Cell Biol*. 2000;20:556-562.
  79. Williams S, Gillan E, Knoppel E, Buzby J, Suen Y, Cairo M. Effects of phosphodiester and phosphorothioate antisense oligodeoxynucleotides on cell lines which overexpress c-myc: implications for the treatment of Burkitt's lymphoma. *Ann Oncol*. 1997;8:25-30.
  80. Smith J, Wickstrom E. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model. *J Natl Cancer Inst*. 1998;90:1146-1154.
  81. Orlowski R, Eswara J, Orlowski M, Dang C. Novel demonstration of tumor growth delay in a murine model of human Burkitt's lymphoma after treatment with a proteasome inhibitor. *Proc Am Soc Clin Oncol [abstract]*. 1998;1717.
  82. Serafeim A, Holder M, Grafton G, et al. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. *Blood*. 2003;101:3212-3219.
  83. Serafeim A, Grafton G, Chamba A, et al. 5-Hydroxytryptamine drives apoptosis in biopsylake Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors. *Blood*. 2002;99:2545-2553.
  84. Spina M, Tirelli U, Zagonel V, et al. Burkitt's lymphoma in adults with and without Human Immunodeficiency Virus infection. *Cancer*. 1998;82:766-774.
  85. Hamilton-Dutoit S, Raphael M, Audouin J, et al. In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: correlation with tumor morphology and primary site. *Blood*. 1993;82:619-624.
  86. Subar M, Neri A, Inghirami G, Knowles D, Dalla-Favera R. Frequent c-myc oncogene activation and infrequent presence of Epstein-Barr virus genome in AIDS-associated lymphoma. *Blood*. 1998;72:667-671.
  87. Farrell C, Lee J, Shin E, Cebrat M, Cole P, Hayward S. Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide. *Proc Natl Acad Sci U S A*. 2004;101:4625-4630.
  88. Kennedy G, Komano J, Sugden B. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. *Proc Natl Acad Sci U S A*. 2003;100:14269-14274.

## Erratum

In the article by Banker et al entitled "Cholesterol synthesis and import contribute to protective cholesterol increments in acute myeloid leukemia cells," which appeared in the September 15, 2004, issue of *Blood* (Volume 104:1816-1824), the row headings and 2 footnote callouts were incorrect in Table 4. The table appears below with the correct row headings and footnote callouts.

**Table 4. Correlations for LDL accumulation**

	No. increments	r <sup>2</sup>	P
LDL + DNR	5	.88*	.01
LDL + DNR + MEV	5	.85*	.03
LDL + ARA-C	6	-.18†	.73
LDL + ARA-C + MEV	6	-.21†	.68

\*with chol + DNR.

†with chol + ARA-C.